Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: molidustat, daprodustat, roxadustat +1 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 212 | 0.85 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 16714
Sealed predictions
- EGLN3 in dopamine neurons, braak+0.13 (p 0.732) → -0.12 (p 0.756)receipt 16721
Swarm cases
receipt 16721: EGLN3 in dopamine neurons, braak
- power
- full sample -0.07 (p 0.794, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.07 (p 0.794, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.06 (p 0.807, n 18). could be the mix.
- skeptic
- leave-one-out range -0.17 to +0.05, sign flips 4; without severely affected donors -0.07 (p 0.794, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EGLN3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts